NASDAQ:CODX • US1897631057
The current stock price of CODX is 2.36 USD. In the past month the price decreased by -76.96%. In the past year, price decreased by -90.1%.
ChartMill assigns a fundamental rating of 4 / 10 to CODX. While CODX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months CODX reported a non-GAAP Earnings per Share(EPS) of -19.26. The EPS decreased by -1416.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.93% | ||
| ROE | -80.8% | ||
| Debt/Equity | 0 |
8 analysts have analysed CODX and the average price target is 38.25 USD. This implies a price increase of 1520.76% is expected in the next year compared to the current price of 2.36.
For the next year, analysts expect an EPS growth of -1795.58% and a revenue growth -88.3% for CODX
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.78 | 198.44B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.67 | 176.233B | ||
| SYK | STRYKER CORP | 25.44 | 148.004B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.09 | 113.036B | ||
| IDXX | IDEXX LABORATORIES INC | 42.89 | 50.84B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.68 | 50.591B | ||
| BDX | BECTON DICKINSON AND CO | 11.06 | 50.298B | ||
| RMD | RESMED INC | 21.03 | 37.497B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.56 | 36.533B | ||
| DXCM | DEXCOM INC | 28.94 | 28.776B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Co-Diagnostics Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
CO-DIAGNOSTICS INC
2401 S. Foothill Dr. Suite D
Salt Lake City UTAH 84109 US
CEO: Dwight Egan
Employees: 132
Phone: 18014381036
Co-Diagnostics Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
The current stock price of CODX is 2.36 USD. The price decreased by -60.54% in the last trading session.
CODX does not pay a dividend.
CODX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
CO-DIAGNOSTICS INC (CODX) has a market capitalization of 143.70M USD. This makes CODX a Micro Cap stock.
CO-DIAGNOSTICS INC (CODX) will report earnings on 2026-03-25, after the market close.
The outstanding short interest for CO-DIAGNOSTICS INC (CODX) is 0.02% of its float.